Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03WAU
|
|||
| Former ID |
DCL000049
|
|||
| Drug Name |
Anamorelin
|
|||
| Synonyms |
249921-19-5; UNII-DD5RBA1NKF; DD5RBA1NKF; RC 1291; Anamorelin [INN]; ONO-7643; SCHEMBL935751; CHEMBL2110579; EX-A154; DTXSID20179702; C31H42N6O3; BCP06108; 3444AH; ZINC43130908; AKOS030526752; SB16911; API0008642; RC-1291; NCGC00378854-01; KB-80338; HY-14734; BC600755; (3R)-1-(2-Methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide; AB0165721; FT-0773543; W-5500; 921A195; CS 1036
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Carbohydrate metabolism disorder [ICD-11: 5C51.Z] | Phase 3 | [1] | |
| Company |
Sapphire Therape.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C31H42N6O3
|
|||
| Canonical SMILES |
CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)N3CCCC(C3)(CC4=CC=CC=C4)C(=O)N(C)N(C)C)N
|
|||
| InChI |
1S/C31H42N6O3/c1-30(2,32)28(39)34-26(18-23-20-33-25-15-10-9-14-24(23)25)27(38)37-17-11-16-31(21-37,29(40)36(5)35(3)4)19-22-12-7-6-8-13-22/h6-10,12-15,20,26,33H,11,16-19,21,32H2,1-5H3,(H,34,39)/t26-,31-/m1/s1
|
|||
| InChIKey |
VQPFSIRUEPQQPP-MXBOTTGLSA-N
|
|||
| CAS Number |
CAS 249921-19-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Alpha-glucosidase (GLA) | Target Info | Modulator | [2], [3] |
| Growth hormone secretagogue receptor 1 (GHSR) | Target Info | Stimulator | [4] | |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01395914) Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3). U.S. National Institutes of Health. | |||
| REF 2 | Absorption, elimination, and metabolism of CS-1036, a novel -amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.Drug Metab Dispos.2013 Apr;41(4):878-87. | |||
| REF 3 | Alpha-amylase inhibitor, CS-1036 binds to serum amylase in a concentration-dependent and saturable manner.Drug Metab Dispos.2014 Mar;42(3):326-33. | |||
| REF 4 | Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res. 2009 Jun;19(3):267-73. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.